pixantrone has been researched along with piperazine in 1 studies
| Studies (pixantrone) | Trials (pixantrone) | Recent Studies (post-2010) (pixantrone) | Studies (piperazine) | Trials (piperazine) | Recent Studies (post-2010) (piperazine) |
|---|---|---|---|---|---|
| 92 | 16 | 59 | 1,139 | 8 | 521 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ahonen, T; Airavaara, M; Kalso, E; Leino, S; Mätlik, K; Moreira, VM; Rinne, M; Salminen, O; Vedovi, F; Xhaard, H; Yli-Kauhaluoma, J; Zappia, G | 1 |
1 other study(ies) available for pixantrone and piperazine
| Article | Year |
|---|---|
Mitoxantrone, pixantrone and mitoxantrone (2-hydroxyethyl)piperazine are toll-like receptor 4 antagonists, inhibit NF-κB activation, and decrease TNF-alpha secretion in primary microglia.
Topics: Isoquinolines; Microglia; Mitoxantrone; NF-kappa B; Piperazine; Toll-Like Receptor 4; Tumor Necrosis Factor-alpha | 2020 |